An ELISA Platform for the Quantitative Analysis of SARS-CoV-2 RBD-neutralizing Antibodies As an Alternative to Monitoring of the Virus-Neutralizing Activity
Kostin N, Bobik T, Skryabin G, Simonova M, Knorre V, Abrikosova V, Mokrushina Y, Smirnov I, Aleshenko N, Kruglova N, Mazurov D, Nikitin A, Gabibov A. An ELISA Platform for the Quantitative Analysis of SARS-CoV-2 RBD-neutralizing Antibodies As an Alternative to Monitoring of the Virus-Neutralizing Activity. Acta Naturae 2022, 14: 109-119. PMID: 36348715, PMCID: PMC9611858, DOI: 10.32607/actanaturae.11776.Peer-Reviewed Original ResearchVirus-neutralizing activitySARS-CoV-2Levels of SARS-CoV-2 neutralizing antibodiesSARS-CoV-2 neutralizing antibodiesNeutralizing activity of seraGroup of hospitalized patientsSARS-CoV-2 vaccinesImmunity to SARS-CoV-2Gam-COVID-Vac vaccineActivity of seraHumoral immune responseSARS-CoV-2 infectionGam-COVID-VacNeutralizing antibodiesImmune plasmaSerum immunoglobulinsHospitalized patientsImmune responseELISA platformVirus assayProtective effectAntibodiesHerd immunity to SARS-CoV-2VaccineVirus variants
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply